In this regard, targeting STAT3 with small molecules acting at different levels of this pathway, such as OPB-51602, reduces OXPHOS activity and results in mitochondrial dysfunction, proving to be an effective strategy to overcome metabolic reprogramming characterizing resistant oncogene-addicted cancers [72,73,74]. Here, STAT3 is linked to cancer.